PMID- 20854434
OWN - NLM
STAT- MEDLINE
DCOM- 20110427
LR  - 20181201
IS  - 1365-2133 (Electronic)
IS  - 0007-0963 (Linking)
VI  - 164
IP  - 1
DP  - 2011 Jan
TI  - Analysis of cytokine secretion from lymphocytes of patients with hypersensitivity 
      reactions to contaminated heparins.
PG  - 68-75
LID - 10.1111/j.1365-2133.2010.10055.x [doi]
AB  - BACKGROUND: Beginning in 2007, anaphylactoid reactions associated with 
      unfractionated heparin (UFH) occurred and resulted in some fatalities. These 
      reactions were reported to be linked to the complement and contact system 
      activation induced by certain batches of UFH containing the adulterant 
      oversulphated chondroitin sulphate (OSCS). OBJECTIVES: Drug-specific secretion of 
      selected cytokines from peripheral blood mononuclear cells (PBMC) of patients 
      with hypersensitivity reactions to contaminated heparin was compared with the 
      respective in vitro cytokine pattern of individuals with or without 
      hypersensitivity to heparin, different glycosaminoglycans or other drugs. 
      METHODS: Study individuals (n = 13) were classified as follows: patients with 
      hypersensitivity reactions to contaminated (OSCS) heparin (n = 3), 
      noncontaminated heparin (n = 1) or other compounds (n = 3) and patients with 
      ongoing heparin therapy without symptoms of intolerance (n = 2). Four healthy 
      individuals served as controls. PBMC were incubated with six different 
      glycosaminoglycan structures. Drug-specific intracellular interleukin (IL)-5, 
      interferon (IFN)-gamma and IL-10 production was investigated by flow cytometry, while 
      secretion of IL-5, IL-2 and IFN-gamma was analysed by enzyme-linked immunosorbent 
      assay. RESULTS: PBMC from individuals with hypersensitivity reactions to 
      contaminated heparin secreted considerable amounts of IL-2 in vitro. There was a 
      suggestion that ongoing heparin therapy and the Li-heparin in the vials may have 
      an impact on the lymphocyte reactivity of PBMC. CONCLUSIONS: The in vitro 
      lymphocyte reactivity pattern of PBMC from individuals with hypersensitivity 
      reactions to contaminated heparins was neither typical for an immune-mediated nor 
      for a nonimmune-mediated reaction. Possible effects of heparins in the test 
      system itself may require consideration.
CI  - (c) 2011 The Authors. BJD (c) 2011 British Association of Dermatologists 2011.
FAU - Martin, M
AU  - Martin M
AD  - Federal Institute for Drugs and Medical Devices, 53175 Bonn, Germany. 
      mail@marion-martin.info
FAU - Ott, H
AU  - Ott H
FAU - Merk, H F
AU  - Merk HF
FAU - Sachs, B
AU  - Sachs B
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Dermatol
JT  - The British journal of dermatology
JID - 0004041
RN  - 0 (Anticoagulants)
RN  - 0 (Cytokines)
RN  - 0 (Glycosaminoglycans)
RN  - 0 (Interleukin-2)
RN  - 0 (Interleukin-5)
RN  - 130068-27-8 (Interleukin-10)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 9005-49-6 (Heparin)
RN  - 9007-28-7 (Chondroitin Sulfates)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anaphylaxis/chemically induced/*immunology
MH  - Anticoagulants/*adverse effects
MH  - Basophils/immunology
MH  - Chondroitin Sulfates/adverse effects
MH  - Cytokines/*immunology/metabolism
MH  - *Drug Contamination
MH  - Drug Hypersensitivity/*immunology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Flow Cytometry
MH  - Glycosaminoglycans/adverse effects
MH  - Heparin/*adverse effects/chemistry
MH  - Humans
MH  - Interferon-gamma/blood
MH  - Interleukin-10/blood
MH  - Interleukin-2/blood
MH  - Interleukin-5/blood
MH  - Lymphocytes/drug effects/*immunology/metabolism
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Young Adult
EDAT- 2010/09/22 06:00
MHDA- 2011/04/28 06:00
CRDT- 2010/09/22 06:00
PHST- 2010/09/22 06:00 [entrez]
PHST- 2010/09/22 06:00 [pubmed]
PHST- 2011/04/28 06:00 [medline]
AID - 10.1111/j.1365-2133.2010.10055.x [doi]
PST - ppublish
SO  - Br J Dermatol. 2011 Jan;164(1):68-75. doi: 10.1111/j.1365-2133.2010.10055.x.